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ABSTRACT
A six years old male child presented with tremor, ataxia, speech apraxia, supranuclear gaze palsy and hepatosplenomegaly.
There was no history of seizures and psycho-cognitive abnormalities. The clinical and bone marrow findings were
consistent with Gaucher's disease type 3.
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INTRODUCTION

was no family history of similar illness or progressive
neurological deterioration. His developmental history
had been normal till the age of 4 year. He was born
full term by spontaneous vertex delivery and he had
been fully immunized.

Gaucher's disease (G.D) is the most common inherited
lysosomal storage disorder due to deficiency of acid
beta glucosidase1. It is divided into 3 types1, 2. Type 1
is a chronic non-neuropathic form of the G.D involving
mainly viscera and blood forming cells. Type 2 is an
acute neuropathic rapidly fatal form of the G.D presented
in infancy. It rapidly progressive leads to death at the
age of two years. It presents with dysphagia, persistent
head hyperextension, paralytic strabismus, trismus,
generalized spasticity and psychomotor regression. Type
3 is a chronic neuropathic form of disease presented
mostly in childhood with progressive myoclonic epilepsy,
horizontal supranuclear gaze palsy, dementia ataxia,
spasticity, while systemic illness tends to be mild2.

On examination he was pale, conscious and alert,
normal facies and no obvious dysmorphic features. His
height was at 10th percentile. His weight was below
the 5th percentile. His head circumference was at 10%
percentile. His higher mental function seemed normal
for his age. His speech was staccato and there was an
obvious tremor in his hands which were coarse and
aggravated with voluntary movements. Eye examination
shows nystagmus and upward gaze palsy and fundus
examination was normal. He was hypotonic with brisk
deep tendon reflexes with bilaterally up going planters.
The remaining cranial nerves were intact and fundus
was normal. His liver was 2cm below right costal margin
and spleen was 7cm enlarged.

CASE REPORT
A six years old male child presented with difficulty in
writing, walking and speaking since the age of 4 years.
His problem first came to light when he was sent to
school and the teacher noted that his hand shook
whilst writing, later on his condition worsened and he
kept tripping and falling during walking which eventually
progressed to the extend that at the time of admission
he was only able to sit up on the chair. His speech has
also changed and according to the mother he was slow
in initiation of his speech and in completing the
sentences. He also tended to break up words while
speaking. He had drooling of his saliva and he was
gradually loosing weight. There was no loss of
consciousness and no episode of reported seizures.
He is the 4th issue of consanguineous marriage. There
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Investigation done including complete blood count
which showed microcytic hypochromic anemia. His
serum electrolytes, RBS, SGPT, Serum lactic acid,
Serum ammonia, and cerulloplasmin and vitB12 level
were within normal limits. His urine for reducing
substance and ketones were negatives. His X-rays of
chest and femur were normal and did not show any
dysostosis multiplex. His EEG and EMG/NCV were
normal. His MRI showed high intensity signals in
peritrigonal white matter bilaterally extending in the
supraventricular areas with almost symmetrical
appearance. His bone marrow examination showed
increased foamy histiocytes that constitute 10% of the
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total nucleated cell population (fig 1). In PAS staining
foamy histiocytes were seen. The final diagnosis was
therefore consistent with Gaucher's disease type 3.

neurological involvement, heart valve calcification and
specific gene mutation (D409H) 9. Norbottnian variant
in Northern Spain present in childhood with aggressive
systemic disease and slowly progressive heterogeneous
neurological syndrome including horizontal supranuclear
gaze palsy, dementia, spasticity, ataxia and myoclonic
or complex partial seizures. They have single mutation
L444P9.

DISCUSSION
Gaucher's disease (GD) is an autosomal recessive
inherited form of lysosomal disorder caused by deficiency
of lysosomal enzyme glucocerebrosidase resulting in
pathological accumulation of glycolipid in mononuclear
phagocytic system1. Conventionally it is divided into
three clinical phenotypes 1 . Partial deficiency of
glucocerebrosidase is associated principally with
hepatosplenomegaly, features of hypersplenism, skeletal
manifestation and in severe cases; lung is involved, in
non neuropathic, type 1 gaucher's disease. Here storage
material in macrophages originates from turnover of
exogenous glycolipid. Severe deficiency of
glucocerebrosidase caused by disabling mutation is
additionally associated with neurological manifestation
that in part reflects failure to degrade endogenous
neuronal glycosphingolipid, the so called type 2 and 3
disease categories2.

In NGD 20 different gene mutation has been identified.
Lack of shared genotype and variability in clinical
manifestation suggest that other modifications are also
present6, 9. The most common mutation observed is
L444P6. The second most common mutation is R463C10.
The major clinical finding shared by all patients is
horizontal saccadic eye movement irrespective of visceral
involvement 12 . The Patterson at all suggests that
occulomotor abnormality is predictor of several visceral
involvement6. Gaucher cells are related to monocytehistiocyte series. They are large and average 20 to 60
micm in cross-section with wrinkled cytoplasm. Abundant
acid phosphatase activity is noted. The pathogenesis
of neuronal dysfunction is a not known although most
striking microscopic feature found in brain is the
perivascular accumulation of gaucher cells in the
Virchow-Robin spaces2. The diagnosis is made by
decreased glucocerebrosidase activity in lymphocytes
or fibroblast and molecular analysis of mutation allow
for some prognostic action of disease severity and
presence of foam cells on bone marrow examination
helpful in establishing the diagnosis13.

Patient with GD with neurological manifestation was
first reported in 19203. Type 2 Gaucher's disease, is
an acute neuropathic form, has an incidence of
1:5000002. It presents during infancy with a neurological
syndrome characterized by dysphagia, persistent head
hyperextention, paralytic strabismus, trismus, generalized
spasticity, myoclonic or generalized tonic-clonic seizure
and psychomotor regression2, 4. Icthyosiform skin may
provide a mean for early differentiation of type 2 and
type 3 Gaucher's disease5. Death usually occurs by
the age of 2 years as a result of progressive brainstem
dysfunction4.

Figure 1 Gaucher cells (foamy Histiocytes) on the bone
marrow examination.

Type 3 or subacute or chronic neuropathic form of
Gaucher's disease has an incidence of 1:200,0002. It
is phenotypically heterogeneous and had wide variation
in age of presentation. Common childhood age of
presentation is 4 years6, 7, 8. The features were also
seen in our patient who also had his first symptoms
starting at age 4 years. Four subtypes are distinguishable
on clinical ground. 3A, 3B, 3C and Norbottnian variant.
Type 3A present in children and young adult with seizure,
gaze palsy, ataxia, spasticity and developmental
regression6, 7, 8. Type 3B present in childhood and the
children with aggressive systemic disease, gaze palsy
and cognitive impairment leading to death in adolescence
from the complication of portal and pulmonary
hypertention3, 6. Type 3C has recently been described
in Arab patients, in Israel and Spain in 19959. They
suffer from abnormal eye movement but no other
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Four forms of management have been described.
Splenectomy has long been treatment of choice to
avoid hypersplenism or to relieve pressure symptoms
but still it had been matter of debate13. Now a day
enzyme replacement therapy is a highly efficacious
treatment for the hematological, visceral, and skeletal
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manifestations of GD, this remains the first line of
therapy13. It prolongs the lives of individual patient, but
its use in type 3 is still contravertial12, 14.The allogenic
bone marrow transplantation improves the hematological
and visceral manifestation but it has significant mortality
and morbidity therefore it's limited in use12. The goal
of gene therapy is to provide tissue with enzyme level
allowing avoiding storage of undigested substrate
13, 15
. NGD is difficult to target by gene therapy because
of no soluble nature of glucocerebrosidase12, 13. Studies
of gene therapy in animal models of GD show promise,
but this research is still preclinical15.
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